Reducing Lung Cancer Survivors' Anxiety (RELAX) Save

Date Added
February 1st, 2016
PRO Number
Pro00051586
Researcher
Patricia Griffin
Keywords
Anxiety, Breathing, Cancer, Cancer/Lung, Shortness of Breath
Summary

The purpose of this research study is to determine ability to recruit early-stage lung cancer survivors who have completed cancer treatment to a study of a device that may decrease anxiety. Researchers then will determine how many will complete the sessions using the study device as well as all study questionnaires. They will also compare effects of device-guided breathing on anxiety and shortness of breath in lung cancer survivors.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) Save

Date Added
February 4th, 2014
PRO Number
Pro00032186
Researcher
Patricia Griffin
Keywords
Cancer, Cancer/Lung, Drug Studies
Summary

Cancer is a disease caused by alterations in the functions of genes within the cells. In approximately 15% of patients with non-small cell lung cancer, one of two genes is altered significantly (known as EGFR mutation or ALK rearrangement). Erlotinib, a pill, taken on a daily basis produces significant decrease in the size of tumors in patients with advanced stage lung cancer with EGFR mutation. Similarly, another pill, crizotinib, produces significant decrease in the size of tumors in patients with advanced stage lung cancer with ALK rearrangement. However it is not clear how useful these two drugs will be in patients with a less advanced form of lung cancer in the presence of these gene alterations.

The purpose of this study is to find out what effects, good and/or bad, one of the following treatments have on locally advanced, non-operable lung cancer with specific gene alterations (EGFR mutation or ALK rearrangement).

If the tumor has EGFR mutation, subjects will be randomized to either
? Standard treatment: radiation therapy and chemotherapy
or
? Experimental treatment #1: erlotinib for three months, then radiation therapy and chemotherapy

If the tumor has ALK rearrangement, subjects will be randomized to either
? Standard treatment: radiation therapy and chemotherapy
or
? Experimental treatment #2: crizotinib for three months, then radiation therapy and chemotherapy

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY/STEREOTACTIC RADIOSURGERY IN COMBINATION WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER - A COLLABORATIVE STUDY OF NRG ONCOLOGY AND KROG Save

Date Added
May 7th, 2013
PRO Number
Pro00025233
Researcher
Patricia Griffin
Keywords
Cancer, Cancer/Brain, Drug Studies
Summary

The purpose of this study is to compare the effects of adding lapatinib to standard whole brain radiation therapy (WBRT). The study will try to find out whether WBRT or lapatinib plus WBRT is better at safely improving tumor control. In this study, subjects will receive either lapatinib plus WBRT or WBRT alone.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

Change_preferences

-- OR --

Create_login